Dr Geert-Jan Mulder

Managing Partner at Forbion Capital Partners

Geert-Jan Mulder, Managing Partner at Forbion, co-founded the fund in 2006 and currently serves on the Board of several Forbion portfolio companies. Led the firm’s successful investment in 2004 in bluebirdbio (NASDAQ: BLUE), which went public in 2013, supported the company in clinical development and served as the chairman for several years. Other investments include Acorda Therapeutics (NASDAQ:ACOR), which went public in 2006; PanGenetics B.V. which sold to Abbott in 2009, led the Series B financing round; at Transave Inc. supported the company’s clinical development for ARIKAYCE® (liposomal amikacin for inhalation) partly as interim CMO, and served on the Board of Directors till the merger with Insmed (NASDAQ: INSM) in 2010; led the Series A of Exosome Diagnostics in the field of liquid biopsy in 2010 which was acquired by Bio-Techne in 2018; Promedior, led the Series C financing round in 2010 and participated in setting up and executing its clinical development plan, for an antifibrotic treatment of Idiopathic Lung Fibrosis (IPF) and Myelofibrosis, received Breakthrough Therapy Designation by the FDA for IPF and being phase III ready at the time of its acquisition by Roche in 2020; led Forbion’s invested in KaNDy Therapeutics, acquired by Bayer in 2020; and led the investment in Enterprise Therapeutics towards the sale of its TMEM16 program to Roche in 2020.

In addition he is a co-author of several Forbion and Forbion portfolio related scientific publications. Prior to Forbion Geert-Jan was a Resident in in OBGYN and worked several years in the pharmaceutical industry in clinical development and global medical marketing for both Searle (now Pfizer) and Byk Gulden (now Takeda).